Release: NVHR Welcomes Two Federal Actions to Help Prevent and Treat Hepatitis B

Mar 07, 2018 | Kim Rodgers

Below is a press release from the National Viral Hepatitis Roundtable.

CDC Recommended HEPLISAV-B Vaccine to Prevent Hepatitis B in Adults; FDA Granted Orphan Drug Designation to Tenofovir Exalidex (TXL) to Treat the Virus in Children

SAN FRANCISCO, CA (March 5, 2018) – The National Viral Hepatitis Roundtable (NVHR), a national coalition working together to eliminate hepatitis B and hepatitis C in the United States, today welcomed recent action by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) to prevent and treat hepatitis B. Last week, the CDC Advisory Committee on Immunization Practices (ACIP) recommended HEPISLAV-B – which became the first hepatitis B vaccine approved in the United States in more than 25 years when it was licensed by the FDA in November 2017 – to vaccinate adults against hepatitis B. Also last week, the FDA granted Orphan Drug Designation to tenofovir exalidex (TXL) to help fast-track the treatment of hepatitis B in pediatric patients (ages 0-11 years old).

“Results-driven federal action is needed to stem the tide of hepatitis B infections in the U.S.,” said Dr. Robert Gish, NVHR Executive Committee Vice Chair. “The CDC’s recommendation of HEPLISAV-B and the FDA’s Orphan Drug Designation of TXL represent a significant step forward for patients living with hepatitis B. We look forward to working with our advocacy partners to ensure widespread access to this revolutionary vaccine among adults and to this novel treatment for infected children.”

Hepatitis B is an extremely infectious and potentially deadly virus affecting up to 2 million people in the United States. Asian Americans and Pacific Islanders are disproportionately impacted, accounting for more than 50 percent of people living with chronic hepatitis B in the country. While there is effective treatment for hepatitis B, there is no cure and infections are on the rise. In 2015, new cases of acute hepatitis B increased by more than 20 percent, largely as a result of the nation’s opioid crisis.

In March 2017, the National Academies of Sciences, Medicine and Engineering released A National Strategy for the Elimination of Hepatitis B and C. The National Academies noted that only a quarter of adults over the age of 19 have been fully immunized against hepatitis B and called for expanded access to vaccination as part of the overall strategy to eliminate the public health threat of hepatitis B in the United States by 2030. Approved by the FDA on November 9, 2017, HEPLISAV-B is the first new hepatitis B vaccine licensed in the U.S. in more than 25 years. Previous hepatitis B vaccines required three shots over a six-month period for full protection; however, almost half of adults failed to complete the series within one year. HEPLISAV-B is a two-dose vaccination taken over a one-month period, increasing the likelihood of successful completion.

Hepatitis B infection rates remain high among children who are infected at birth or in early childhood. Current pediatric (and adult) treatment options are generally lifelong, painful, and ineffective. In contrast, TXL is a novel hepatitis B treatment with few side effects and has potential to become part of a curative combination therapy for the virus. On February 21, 2018, the FDA granted TXL Orphan Drug Designation, which qualifies the treatment for seven years of market exclusivity in the U.S. upon

approval, financial assistance in clinical research and development, and an accelerated evaluation of the registration package by the FDA.

“The National Academies report confirms that hepatitis B elimination is within reach,” Tina Broder, NVHR Interim Executive Director. “We encourage the federal government to continue to take steps to ensure that all at-risk Americans get vaccinated for hepatitis B and to connect those living with the virus with the best treatments available.”

About the National Viral Hepatitis Roundtable (NVHR)
The National Viral Hepatitis Roundtable is a national coalition working together to eliminate hepatitis B and hepatitis C in the United States. Our vision a healthier world without hepatitis B and hepatitis C. For more information, visit www.nvhr.org.


About Kim Rodgers

Pronouns: She/Her

Kim Rodgers was formerly the Communications Manager at NACCHO.

More posts by Kim Rodgers

Related Posts

  • Webinar

UPCOMING WEBINAR: 2024 National Strategy for Suicide...

Join NACCHO on 7/08, 2-3PMET for 2024 National Strategy for Suicide Prevention:...

Jun 18, 2024

UPCOMING WEBINAR: 2024 National Strategy for Suicide...

6 Networked Partnerships 2022 10 07 133244 rmva

UPCOMING WEBINAR: Building Strong & Effective Youth and...

Join Community Justice and NACCHO for a crucial policy discussion on gun...

Jun 18, 2024

UPCOMING WEBINAR: Building Strong & Effective Youth and...

Dallas, TX Story From the Field Image
  • Immunization Vaccine Hesitancy

From Hesitation to Vaccination: Reducing Vaccine...

Recent data shows that vaccine hesitancy is becoming an issue of rising concern...

Jun 11, 2024

From Hesitation to Vaccination: Reducing Vaccine...

Family in meadow
  • Chronic Disease Community Health Social Determinants of Health Prevention Research Centers

Webinar Series: A Spotlight on Prevention Research...

PRC Webinar Spotlight: Shining a spotlight on various Prevention Research...

Jun 06, 2024 | Johanna Segovia

Webinar Series: A Spotlight on Prevention Research...

Senior couple hiking forest i Stock 966676942
  • Chronic Disease Community Health Social Determinants of Health Prevention Research Centers

Blog Series: PRC Spotlight on Washington University in...

PRCs are more than just research institutions; they are catalysts for change at...

Jun 05, 2024 | Johanna Segovia

Blog Series: PRC Spotlight on Washington University in...

  • HIV, STI, Viral Hepatitis, and Harm Reduction Digest

Digest (May 22, 2024)

HIV, STI, Hepatitis, and Harm Reduction Digest: May 22, 2024

May 22, 2024

Digest (May 22, 2024)

Website New Episode w Special Guests
  • Press Release Community Health Harm Reduction Maternal, Child, & Adolescent Health

NACCHO’s Podcast From Washington: Update on H5N1 and...

Update on H5N1 and Local Health Department Pilot Program Addresses Substance...

May 17, 2024

NACCHO’s Podcast From Washington: Update on H5N1 and...

  • Tools & Resources Injury and Violence Prevention

New Resource- ACEs Questionnaire Use: Cautions and...

NACCHO releases a new resource: ACEs Questionnaire Use: Cautions and...

May 15, 2024 | Camille Adams

New Resource- ACEs Questionnaire Use: Cautions and...

I Stock 494430421
  • Community Health Success Story Tobacco-Use Prevention

Zoning Policies: A Promising Practice in North Carolina

Limiting tobacco retail density near schools & parks is crucial in tobacco...

May 14, 2024 | Ashley Curtice, Director of Public Education and Communications, North Carolina Department of Health and Human Services

Zoning Policies: A Promising Practice in North Carolina

Back to Top